Treatment of cancer with a raf inhibitor

EP4757793A1Pending Publication Date: 2026-06-17PIERRE FABRE MEDICAMENT SAS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
PIERRE FABRE MEDICAMENT SAS
Filing Date
2024-08-09
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Current therapies targeting RAF kinase activity are ineffective for patients with Class II and III BRAF mutations, representing a significant unmet clinical need in cancer treatment.

Method used

The use of l-tert-butyl-5-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrazole-4-carboxamide, or its pharmaceutically acceptable salt or solvate, as a RAF inhibitor to treat cancers with various BRAF alterations, including Class II and III mutations.

Benefits of technology

This approach demonstrates potent antitumor activity, achieving significant tumor growth inhibition and regression in preclinical models, particularly in cancers with BRAF V600 mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000027_0001
    Figure IMGF000027_0001
  • Figure IMGF000028_0001
    Figure IMGF000028_0001
Patent Text Reader

Abstract

Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
Need to check novelty before this filing date? Find Prior Art